25 XP   0   0   10

Cynata Therapeutics Ltd
Buy, Hold or Sell?

Let's analyse Cynata together

PenkeI guess you are interested in Cynata Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cynata Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cynata Therapeutics Ltd

I send you an email if I find something interesting about Cynata Therapeutics Ltd.

Quick analysis of Cynata (30 sec.)










What can you expect buying and holding a share of Cynata? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.09
Expected worth in 1 year
A$-0.07
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
A$-0.16
Return On Investment
-80.5%

For what price can you sell your share?

Current Price per Share
A$0.20
Expected price per share
A$0.175 - A$0.23
How sure are you?
50%

1. Valuation of Cynata (5 min.)




Live pricePrice per Share (EOD)

A$0.20

Intrinsic Value Per Share

A$-1.06 - A$-0.57

Total Value Per Share

A$-0.96 - A$-0.48

2. Growth of Cynata (5 min.)




Is Cynata growing?

Current yearPrevious yearGrowGrow %
How rich?$10.7m$15.4m-$4.6m-43.2%

How much money is Cynata making?

Current yearPrevious yearGrowGrow %
Making money-$9.2m-$3.5m-$5.6m-61.9%
Net Profit Margin-863.0%-70.1%--

How much money comes from the company's main activities?

3. Financial Health of Cynata (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#668 / 1009

Most Revenue
#494 / 1009

Most Profit
#542 / 1009

Most Efficient
#789 / 1009

What can you expect buying and holding a share of Cynata? (5 min.)

Welcome investor! Cynata's management wants to use your money to grow the business. In return you get a share of Cynata.

What can you expect buying and holding a share of Cynata?

First you should know what it really means to hold a share of Cynata. And how you can make/lose money.

Speculation

The Price per Share of Cynata is A$0.2. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cynata.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cynata, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.09. Based on the TTM, the Book Value Change Per Share is A$-0.04 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cynata.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.05-25.6%-0.05-25.6%-0.02-9.8%-0.03-14.2%-0.02-10.8%
Usd Book Value Change Per Share-0.03-13.0%-0.03-13.0%-0.02-7.9%0.000.5%0.012.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.03-13.0%-0.03-13.0%-0.02-7.9%0.000.5%0.012.7%
Usd Price Per Share0.08-0.08-0.23-0.37-0.42-
Price to Earnings Ratio-1.57--1.57--11.88--16.35--23.92-
Price-to-Total Gains Ratio-3.11--3.11--14.65--8.35--33.54-
Price to Book Ratio1.34-1.34-2.70-6.83-9.08-
Price-to-Total Gains Ratio-3.11--3.11--14.65--8.35--33.54-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.12904
Number of shares7749
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.030.00
Usd Total Gains Per Share-0.030.00
Gains per Quarter (7749 shares)-201.147.50
Gains per Year (7749 shares)-804.5529.98
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-805-81503020
20-1609-162006050
30-2414-242509080
40-3218-32300120110
50-4023-40350150140
60-4827-48400180170
70-5632-56450210200
80-6436-64500240230
90-7241-72550270260
100-8045-80600300290

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.016.01.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%8.09.00.047.1%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.017.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%8.09.00.047.1%

Fundamentals of Cynata

About Cynata Therapeutics Ltd

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.

Fundamental data was last updated by Penke on 2024-04-21 01:57:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cynata Therapeutics Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cynata earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cynata to the Biotechnology industry mean.
  • A Net Profit Margin of -863.0% means that $-8.63 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cynata Therapeutics Ltd:

  • The MRQ is -863.0%. The company is making a huge loss. -2
  • The TTM is -863.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-863.0%TTM-863.0%0.0%
TTM-863.0%YOY-70.1%-793.0%
TTM-863.0%5Y-426.0%-437.1%
5Y-426.0%10Y-1,660.2%+1,234.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-863.0%-200.1%-662.9%
TTM-863.0%-216.8%-646.2%
YOY-70.1%-288.3%+218.2%
5Y-426.0%-449.1%+23.1%
10Y-1,660.2%-605.5%-1,054.7%
1.1.2. Return on Assets

Shows how efficient Cynata is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cynata to the Biotechnology industry mean.
  • -75.2% Return on Assets means that Cynata generated $-0.75 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cynata Therapeutics Ltd:

  • The MRQ is -75.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -75.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-75.2%TTM-75.2%0.0%
TTM-75.2%YOY-20.5%-54.7%
TTM-75.2%5Y-42.3%-32.9%
5Y-42.3%10Y-39.8%-2.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-75.2%-13.3%-61.9%
TTM-75.2%-12.8%-62.4%
YOY-20.5%-11.7%-8.8%
5Y-42.3%-13.9%-28.4%
10Y-39.8%-15.7%-24.1%
1.1.3. Return on Equity

Shows how efficient Cynata is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cynata to the Biotechnology industry mean.
  • -85.3% Return on Equity means Cynata generated $-0.85 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cynata Therapeutics Ltd:

  • The MRQ is -85.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -85.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-85.3%TTM-85.3%0.0%
TTM-85.3%YOY-22.7%-62.6%
TTM-85.3%5Y-46.8%-38.5%
5Y-46.8%10Y-42.7%-4.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-85.3%-16.9%-68.4%
TTM-85.3%-16.1%-69.2%
YOY-22.7%-15.1%-7.6%
5Y-46.8%-19.3%-27.5%
10Y-42.7%-20.2%-22.5%

1.2. Operating Efficiency of Cynata Therapeutics Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cynata is operating .

  • Measures how much profit Cynata makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cynata to the Biotechnology industry mean.
  • An Operating Margin of -1,000.0% means the company generated $-10.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cynata Therapeutics Ltd:

  • The MRQ is -1,000.0%. The company is operating very inefficient. -2
  • The TTM is -1,000.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,000.0%TTM-1,000.0%0.0%
TTM-1,000.0%YOY-88.8%-911.2%
TTM-1,000.0%5Y-519.0%-481.0%
5Y-519.0%10Y-1,751.7%+1,232.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,000.0%-296.2%-703.8%
TTM-1,000.0%-232.5%-767.5%
YOY-88.8%-298.2%+209.4%
5Y-519.0%-492.1%-26.9%
10Y-1,751.7%-632.4%-1,119.3%
1.2.2. Operating Ratio

Measures how efficient Cynata is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 10.00 means that the operating costs are $10.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cynata Therapeutics Ltd:

  • The MRQ is 10.000. The company is inefficient in keeping operating costs low. -1
  • The TTM is 10.000. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ10.000TTM10.0000.000
TTM10.000YOY0.888+9.112
TTM10.0005Y5.190+4.810
5Y5.19010Y18.019-12.829
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.0003.231+6.769
TTM10.0003.310+6.690
YOY0.8883.890-3.002
5Y5.1905.739-0.549
10Y18.0197.876+10.143

1.3. Liquidity of Cynata Therapeutics Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cynata is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.46 means the company has $7.46 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cynata Therapeutics Ltd:

  • The MRQ is 7.460. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.460. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.460TTM7.4600.000
TTM7.460YOY9.326-1.866
TTM7.4605Y11.927-4.467
5Y11.92710Y19.861-7.934
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.4603.890+3.570
TTM7.4604.173+3.287
YOY9.3265.344+3.982
5Y11.9276.126+5.801
10Y19.8616.448+13.413
1.3.2. Quick Ratio

Measures if Cynata is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cynata to the Biotechnology industry mean.
  • A Quick Ratio of 7.33 means the company can pay off $7.33 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cynata Therapeutics Ltd:

  • The MRQ is 7.326. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.326. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.326TTM7.3260.000
TTM7.326YOY9.244-1.918
TTM7.3265Y11.754-4.428
5Y11.75410Y19.727-7.973
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.3263.514+3.812
TTM7.3263.998+3.328
YOY9.2445.380+3.864
5Y11.7546.105+5.649
10Y19.7276.404+13.323

1.4. Solvency of Cynata Therapeutics Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cynata assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cynata to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that Cynata assets are financed with 11.9% credit (debt) and the remaining percentage (100% - 11.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cynata Therapeutics Ltd:

  • The MRQ is 0.119. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.119. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.119TTM0.1190.000
TTM0.119YOY0.097+0.022
TTM0.1195Y0.083+0.036
5Y0.08310Y0.059+0.024
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1190.339-0.220
TTM0.1190.336-0.217
YOY0.0970.271-0.174
5Y0.0830.366-0.283
10Y0.0590.389-0.330
1.4.2. Debt to Equity Ratio

Measures if Cynata is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cynata to the Biotechnology industry mean.
  • A Debt to Equity ratio of 13.5% means that company has $0.14 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cynata Therapeutics Ltd:

  • The MRQ is 0.135. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.135. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.135TTM0.1350.000
TTM0.135YOY0.108+0.027
TTM0.1355Y0.091+0.044
5Y0.09110Y0.064+0.028
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1350.388-0.253
TTM0.1350.402-0.267
YOY0.1080.335-0.227
5Y0.0910.426-0.335
10Y0.0640.461-0.397

2. Market Valuation of Cynata Therapeutics Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cynata generates.

  • Above 15 is considered overpriced but always compare Cynata to the Biotechnology industry mean.
  • A PE ratio of -1.57 means the investor is paying $-1.57 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cynata Therapeutics Ltd:

  • The EOD is -2.516. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.573. Based on the earnings, the company is expensive. -2
  • The TTM is -1.573. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.516MRQ-1.573-0.944
MRQ-1.573TTM-1.5730.000
TTM-1.573YOY-11.876+10.303
TTM-1.5735Y-16.351+14.778
5Y-16.35110Y-23.919+7.568
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.516-2.264-0.252
MRQ-1.573-2.629+1.056
TTM-1.573-2.680+1.107
YOY-11.876-4.145-7.731
5Y-16.351-6.257-10.094
10Y-23.919-6.254-17.665
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cynata Therapeutics Ltd:

  • The EOD is -2.515. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.572. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.572. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.515MRQ-1.572-0.943
MRQ-1.572TTM-1.5720.000
TTM-1.572YOY-19.606+18.034
TTM-1.5725Y-20.836+19.264
5Y-20.83610Y-30.702+9.865
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.515-2.973+0.458
MRQ-1.572-3.333+1.761
TTM-1.572-3.553+1.981
YOY-19.606-5.605-14.001
5Y-20.836-8.376-12.460
10Y-30.702-8.865-21.837
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cynata is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.34 means the investor is paying $1.34 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cynata Therapeutics Ltd:

  • The EOD is 2.147. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.342. Based on the equity, the company is underpriced. +1
  • The TTM is 1.342. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.147MRQ1.342+0.805
MRQ1.342TTM1.3420.000
TTM1.342YOY2.699-1.357
TTM1.3425Y6.830-5.488
5Y6.83010Y9.076-2.246
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.1471.896+0.251
MRQ1.3422.115-0.773
TTM1.3422.093-0.751
YOY2.6992.884-0.185
5Y6.8303.542+3.288
10Y9.0763.916+5.160
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cynata Therapeutics Ltd.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cynata Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.040-0.0400%-0.025-39%0.001-2783%0.008-579%
Book Value Per Share--0.0930.0930%0.133-30%0.108-14%0.085+9%
Current Ratio--7.4607.4600%9.326-20%11.927-37%19.861-62%
Debt To Asset Ratio--0.1190.1190%0.097+22%0.083+44%0.059+103%
Debt To Equity Ratio--0.1350.1350%0.108+25%0.091+48%0.064+112%
Dividend Per Share----0%-0%-0%-0%
Eps---0.079-0.0790%-0.030-62%-0.044-45%-0.034-58%
Free Cash Flow Per Share---0.080-0.0800%-0.018-77%-0.037-54%-0.028-65%
Free Cash Flow To Equity Per Share---0.042-0.0420%-0.017-59%0.004-1086%0.008-603%
Gross Profit Margin--1.0041.0040%1.012-1%1.050-4%1.025-2%
Intrinsic Value_10Y_max---0.574--------
Intrinsic Value_10Y_min---1.058--------
Intrinsic Value_1Y_max---0.034--------
Intrinsic Value_1Y_min---0.059--------
Intrinsic Value_3Y_max---0.121--------
Intrinsic Value_3Y_min---0.219--------
Intrinsic Value_5Y_max---0.228--------
Intrinsic Value_5Y_min---0.423--------
Market Cap35926400.000+38%22454000.00022454000.0000%64667520.000-65%102210608.000-78%115952456.000-81%
Net Profit Margin---8.630-8.6300%-0.701-92%-4.260-51%-16.602+92%
Operating Margin---10.000-10.0000%-0.888-91%-5.190-48%-17.517+75%
Operating Ratio--10.00010.0000%0.888+1026%5.190+93%18.019-45%
Pb Ratio2.147+38%1.3421.3420%2.699-50%6.830-80%9.076-85%
Pe Ratio-2.516-60%-1.573-1.5730%-11.876+655%-16.351+940%-23.919+1421%
Price Per Share0.200+38%0.1250.1250%0.360-65%0.569-78%0.646-81%
Price To Free Cash Flow Ratio-2.515-60%-1.572-1.5720%-19.606+1147%-20.836+1225%-30.702+1853%
Price To Total Gains Ratio-4.971-60%-3.107-3.1070%-14.654+372%-8.350+169%-33.540+979%
Quick Ratio--7.3267.3260%9.244-21%11.754-38%19.727-63%
Return On Assets---0.752-0.7520%-0.205-73%-0.423-44%-0.398-47%
Return On Equity---0.853-0.8530%-0.227-73%-0.468-45%-0.427-50%
Total Gains Per Share---0.040-0.0400%-0.025-39%0.001-2783%0.008-579%
Usd Book Value--10796441.94110796441.9410%15459046.842-30%12494851.453-14%9888882.072+9%
Usd Book Value Change Per Share---0.026-0.0260%-0.016-39%0.001-2783%0.005-579%
Usd Book Value Per Share--0.0600.0600%0.086-30%0.070-14%0.055+9%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.051-0.0510%-0.020-62%-0.028-45%-0.022-58%
Usd Free Cash Flow---9215216.751-9215216.7510%-2128083.161-77%-4244244.962-54%-3213806.107-65%
Usd Free Cash Flow Per Share---0.051-0.0510%-0.012-77%-0.024-54%-0.018-65%
Usd Free Cash Flow To Equity Per Share---0.027-0.0270%-0.011-59%0.003-1086%0.005-603%
Usd Market Cap23179713.280+38%14487320.80014487320.8000%41723483.904-65%65946284.282-78%74812524.611-81%
Usd Price Per Share0.129+38%0.0810.0810%0.232-65%0.367-78%0.416-81%
Usd Profit---9211839.774-9211839.7740%-3513224.974-62%-5100124.828-45%-3892780.456-58%
Usd Revenue--1067360.8121067360.8120%5013478.210-79%2489296.704-57%1537205.517-31%
Usd Total Gains Per Share---0.026-0.0260%-0.016-39%0.001-2783%0.005-579%
 EOD+5 -3MRQTTM+0 -0YOY+3 -315Y+3 -3110Y+9 -25

4.2. Fundamental Score

Let's check the fundamental score of Cynata Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.516
Price to Book Ratio (EOD)Between0-12.147
Net Profit Margin (MRQ)Greater than0-8.630
Operating Margin (MRQ)Greater than0-10.000
Quick Ratio (MRQ)Greater than17.326
Current Ratio (MRQ)Greater than17.460
Debt to Asset Ratio (MRQ)Less than10.119
Debt to Equity Ratio (MRQ)Less than10.135
Return on Equity (MRQ)Greater than0.15-0.853
Return on Assets (MRQ)Greater than0.05-0.752
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Cynata Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.970
Ma 20Greater thanMa 500.193
Ma 50Greater thanMa 1000.187
Ma 100Greater thanMa 2000.159
OpenGreater thanClose0.200
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets18,994
Total Liabilities2,260
Total Stockholder Equity16,733
 As reported
Total Liabilities 2,260
Total Stockholder Equity+ 16,733
Total Assets = 18,994

Assets

Total Assets18,994
Total Current Assets16,861
Long-term Assets2,133
Total Current Assets
Cash And Cash Equivalents 16,167
Short-term Investments 26
Net Receivables 367
Other Current Assets 327
Total Current Assets  (as reported)16,861
Total Current Assets  (calculated)16,887
+/- 26
Long-term Assets
Intangible Assets 2,133
Long-term Assets  (as reported)2,133
Long-term Assets  (calculated)2,133
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,260
Long-term Liabilities0
Total Stockholder Equity16,733
Total Current Liabilities
Accounts payable 1,309
Other Current Liabilities 952
Total Current Liabilities  (as reported)2,260
Total Current Liabilities  (calculated)2,260
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock81,625
Retained Earnings -72,574
Accumulated Other Comprehensive Income 7,683
Total Stockholder Equity (as reported)16,733
Total Stockholder Equity (calculated)16,733
+/-0
Other
Capital Stock81,625
Cash and Short Term Investments 16,167
Common Stock Shares Outstanding 145,092
Liabilities and Stockholders Equity 18,994
Net Debt -16,167
Net Invested Capital 16,733
Net Tangible Assets 16,733
Net Working Capital 14,601



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-30
> Total Assets 
3,557
2,328
1,420
1,249
1,218
1,017
1,793
9,926
9,125
9,031
14,254
16,133
12,250
17,481
29,975
26,548
18,994
18,99426,54829,97517,48112,25016,13314,2549,0319,1259,9261,7931,0171,2181,2491,4202,3283,557
   > Total Current Assets 
3,489
2,181
1,224
972
1,207
1,017
1,150
5,104
4,751
4,937
10,441
12,600
7,330
13,851
27,282
24,135
16,861
16,86124,13527,28213,8517,33012,60010,4414,9374,7515,1041,1501,0171,2079721,2242,1813,489
       Cash And Cash Equivalents 
3,248
2,079
1,005
628
389
993
1,117
5,095
4,704
4,879
10,350
12,206
6,977
13,650
26,717
23,798
16,167
16,16723,79826,71713,6506,97712,20610,3504,8794,7045,0951,1179933896281,0052,0793,248
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
4
4
26
26
26
26262644000000000000
       Net Receivables 
133
100
219
344
510
24
33
10
48
55
88
53
63
17
278
100
367
367100278176353885548103324510344219100133
       Inventory 
106
0
0
0
308
0
-33
-10
-48
-55
-88
-53
-63
0
0
0
0
0000-63-53-88-55-48-10-330308000106
       Other Current Assets 
2
2
83
161
421
0
33
10
48
58
91
394
353
184
287
237
327
327237287184353394915848103304211618322
   > Long-term Assets 
68
146
196
277
11
0
643
4,822
4,374
4,093
3,813
3,533
4,919
3,630
2,693
2,413
2,133
2,1332,4132,6933,6304,9193,5333,8134,0934,3744,82264301127719614668
       Property Plant Equipment 
9
7
2
20
11
0
0
0
0
0
0
0
0
0
0
0
0
0000000000001120279
       Goodwill 
0
0
0
0
0
0
0
4,822
0
0
0
0
0
0
0
0
0
0000000004,8220000000
       Intangible Assets 
58
139
194
256
0
0
0
4,822
4,374
4,093
3,813
3,533
3,253
2,972
2,693
2,413
2,133
2,1332,4132,6932,9723,2533,5333,8134,0934,3744,82200025619413958
       Long-term Assets Other 
0
0
0
0
0
0
-643
-4,822
-4,374
-4,093
-3,813
0
0
658
0
0
0
00065800-3,813-4,093-4,374-4,822-643000000
> Total Liabilities 
147
117
458
317
246
163
150
71
375
447
390
746
1,278
690
1,602
2,588
2,260
2,2602,5881,6026901,27874639044737571150163246317458117147
   > Total Current Liabilities 
147
117
458
317
246
163
150
71
375
447
390
746
1,278
690
1,602
2,588
2,260
2,2602,5881,6026901,27874639044737571150163246317458117147
       Short-term Debt 
0
0
0
0
20
0
0
0
33
0
0
0
0
0
0
0
0
0000000033000200000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
33
0
0
0
0
0
0
0
0
000000003300000000
       Accounts payable 
110
20
10
60
134
17
14
35
153
134
95
299
791
297
676
1,580
1,309
1,3091,58067629779129995134153351417134601020110
       Other Current Liabilities 
38
96
449
257
92
146
136
36
190
314
295
447
487
392
926
1,007
952
9521,00792639248744729531419036136146922574499638
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
791
297
676
1,580
0
01,580676297791000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
3,533
3,253
2,972
2,693
2,413
2,133
2,1332,4132,6932,9723,2533,53300000000000
> Total Stockholder Equity
3,410
2,211
962
932
972
854
1,643
9,855
8,750
8,583
13,865
15,387
10,971
16,791
28,373
23,960
16,733
16,73323,96028,37316,79110,97115,38713,8658,5838,7509,8551,6438549729329622,2113,410
   Common Stock
5,043
5,313
5,514
6,968
9,485
10,914
12,338
22,282
24,460
28,792
38,378
44,192
47,988
57,165
74,900
74,900
81,625
81,62574,90074,90057,16547,98844,19238,37828,79224,46022,28212,33810,9149,4856,9685,5145,3135,043
   Retained Earnings -72,574-58,296-52,851-45,161-41,522-33,050-28,484-23,931-18,991-15,279-12,239-11,324-9,781-7,216-4,751-3,102-1,815
   Accumulated Other Comprehensive Income 
182
548
548
1,180
1,268
1,264
1,544
2,852
3,281
3,722
3,971
4,245
4,506
4,787
6,324
7,356
7,683
7,6837,3566,3244,7874,5064,2453,9713,7223,2812,8521,5441,2641,2681,180548548182
   Capital Surplus 00000000000000000
   Treasury Stock00000000000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.